Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Treasury Shares: 2019-2020

  • Silence Therapeutics' Treasury Shares fell 6.35% to $5.7 billion in Q4 2020 from the same period last year, while for Dec 2020 it was $5.7 billion, marking a year-over-year decrease of 6.35%. This contributed to the annual value of $5.5 billion for FY2020, which is 8.29% down from last year.
  • According to the latest figures from Q4 2020, Silence Therapeutics' Treasury Shares is $5.7 billion, which was down 6.35% from $6.1 billion recorded in Q4 2019.
  • Over the past 5 years, Silence Therapeutics' Treasury Shares peaked at $6.1 billion during Q4 2019, and registered a low of $5.7 billion during Q4 2020.
  • Moreover, its 2-year median value for Treasury Shares was $5.9 billion (2019), whereas its average is $5.9 billion.
  • Data for Silence Therapeutics' Treasury Shares shows a maximum YoY dropped of 6.35% (in 2020) over the last 5 years.
  • Over the past 2 years, Silence Therapeutics' Treasury Shares (Quarterly) stood at $6.1 billion in 2019, then dropped by 6.35% to $5.7 billion in 2020.